Drug Type Interferons |
Synonyms CIFN, IFN Alfacon-1, IFN-consensus + [14] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (06 Oct 1997), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02744 | INTERFERON ALFACON-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | United States | 06 Oct 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Preclinical | Canada | 12 Jul 1999 | |
Non-Hodgkin Lymphoma | Preclinical | Japan | - | |
Ovarian Cancer | Preclinical | European Union | - | |
Virus Diseases | Preclinical | United States | - |
Not Applicable | 133 | Patients treated with IL-2 and IFN before 2007 | jfgasmtrri(iadreqzdno) = mtaiefpker crghugaerr (tqzxzcjhfr ) | - | 20 May 2010 | ||
jfgasmtrri(iadreqzdno) = wkvxrkjbxx crghugaerr (tqzxzcjhfr ) |